Phaseline

Targets › CD11B

CD11B (Integrin alpha-M): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 1, 1 Phase 2; Oncology, Cardiovascular; next expected readout Dec 2026.

Integrin ITGAM/ITGB2 is implicated in various adhesive interactions of monocytes, macrophages and granulocytes as well as in mediating the uptake of complement-coated particles and pathogens. It is identical with CR-3, the receptor for the iC3b fragment of the third complement component. (UniProt, P11215)

Open in Phaseline: the race on CD11B, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Duke UniversityTc 99m tilmanocept
CD11b-targeting radiopharmaceutical; technetium-99m labeled molecular tracer that binds to
CD11BPhase 2Cardiac SarcoidosisDec 2026
Washington University School of MedicineONT01
CD11b agonist
CD11BPhase 1Metastatic Pancreatic Ductal AdenocarcinomaSep 2028

Conditions

Metastatic Pancreatic Ductal Adenocarcinoma (1) Cardiac Sarcoidosis (1)

Modalities

small molecule (1), antibody (1)

Companies

Washington University School of Medicine (1) Duke University (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.